Prof Hans Stauss

Photo

Personal Profile

Name: Hans Stauss Email: h.stauss@ucl.ac.uk
Title: Prof Tel:
Department: Div of Infection & Immunity Fax:
Position: Professor of Tumour Imunology Address: , , ,
Research Domain: Cancer, Experimental Medicine, Global Health, Infection, Immunology & Inflammation, Personalised Medicine Web Page:  

Profile

Research Description

The main focus of our work is the analysis of antigen-specific T lymphocyte responses to tumours and the development of immunotherapy approaches for cancer treatment. The transfer of T cell receptor (TCR) genes provides an exciting strategy to equip patient T lymphocytes with well-characterized TCRs, allowing the gene modified T cells to attack tumour cells. We also use the TCR transfer approach to explore whether it can control EBV associated malignancies and CMV spread in immunosuppressed individuals. Our experimental platform involves extensive in vitro analysis of target antigen expression and the definition of effective T cell responses. We use in vivo murine models to test safety and efficacy of new immunotherapy protocols, and are currently translating our research into phase I/II clinical trials with the goal of establishing effective immunity in patients.

Research Activities

Effect of Tumour Biology on Therapeutic Response

Gene and Cellular Therapy of Haematological Malignancies

The genetics of acute lymphoblastic leukaemia

Transplantation Biology

Education Description

UCL Collaborators

Prof Barbara Pedley; Prof Stephen Mackinnon; Prof Adrian Thrasher; Prof Daniel Hochhauser; Prof Paul Griffiths; Prof Quentin Pankhurst; Prof Ivan Gout; Prof David Linch; Prof Rosemary Gale; Dr Adele Fielding; Prof Paul Beard; Dr Karl Peggs; Prof Samuel Janes; Prof Chris Boshoff; Dr Erik Arstad; Dr Emma Morris; Dr Elisabeth Nacheva

External Collaborators

Publications

    2014

    • Oren R, Hod-Marco M, Haus-Cohen M, Thomas S, Blat D, Duvshani N, Denkberg G, Elbaz Y, Benchetrit F, Eshhar Z, Stauss H, Reiter Y (2014). Functional Comparison of Engineered T Cells Carrying a Native TCR versus TCR-like Antibody-Based Chimeric Antigen Receptors Indicates Affinity/Avidity Thresholds.. J Immunol, , - . doi:10.4049/jimmunol.1301769
    • Qasim W, Brunetto M, Gehring A, Xue SA, Schurich A, Khakpoor A, Zhan H, Ciccorossi P, Gilmour K, Cavallone D, Moriconi F, Farzhenah F, Mazzoni A, Chan L, Morris E, Thrasher A, Maini M, Bonino F, Stauss H, Bertoletti A (2014). Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells targeting HBsAg in a liver transplant patient.. J Hepatol, , - . doi:10.1016/j.jhep.2014.10.001
    • Griffin J, Xue S-A, Carpenter B, Velica P, Holler A, Nicholson E, Stauss H, Pule M, Chakraverty R (2014). T Cells Engineered for Resistance To Mycophenolate Mofetil Demonstrate Enhanced Expansion and Improved Tumour Control in Immunosuppressed Hosts.
    • Uttenthal B, Martinez-Davila I, Ivey A, Craddock C, Chen F, Virchis A, Kottaridis P, Grimwade D, Khwaja A, Stauss H, Morris EC (2014). Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses.. Br J Haematol, 164(3), 366 - 375. doi:10.1111/bjh.12637
    • Stavrou M, Pule M, Shlomchik W, Stauss H (2014). Retroviral transfer for a chimeric antigen receptor (CAR) to generate regulatory T cells for the treatment of autoimmunity and graft versus host disease.
    • Sassi A, Lazaroski S, Wu G, Haslam SM, Fliegauf M, Mellouli F, Patiroglu T, Unal E, Ozdemir MA, Jouhadi Z, Khadir K, Ben-Khemis L, Ben-Ali M, Ben-Mustapha I, Borchani LH, Pfeifer D, Jakob T, Khemiri M, Asplund AC, Gustafsson MO, Lundin KE, Falk-Soerqvist E, Moens LN, Gungor HE, Engelhardt KR, Dziadzio M, Stauss H, Fleckenstein B, Meier R, Prayitno K, Maul-Pavicic A, Schaffer S, Rakhmanov M, Henneke P, Kraus H, Eibel H, Koelsch U, Nadifi S, Nilsson M, Bejaoui M, Schaeffer AA, Smith CIE, Dell A, Barbouche M-R, Grimbacher B (2014). Hypomorphic homozygous mutations in phosphoglucomutase 3 (PGM3) impair immunity and increase serum IgE levels. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 133(5), 1410 - U681. doi:10.1016/j.jaci.2014.02.025
    • Richardson R, Tendeiro R, Nicholson E, Xue S-A, Pulham T, Zhan H, Qasim W, Stauss H, Morris E (2014). CMV TCR gene therapy: a phase I safety, toxicity and feasibility study of adoptive immunotherapy with CMV TCR-transduced donor-derived T cells for recipients of allogeneic haematopoietic stem cell transplantation (CMV TCR-001).

    2013

    • Snauwaert S, Verstichel G, Bonte S, Goetgeluk G, Vanhee S, Van Caeneghem Y, De Mulder K, Taghon T, Leclercq G, Plum J, Kerre T, Vandekerckhove B, Heirman C, Thielemans K, Stauss H, Heemskerk MHM, Langerak AW (2013). In vitro generation of mature, naive antigen-specific CD8 T cells with a single T-cell receptor by agonist selection. Leukemia, , - . doi:10.1038/leu.2013.285
    • Koh S, Shimasaki N, Suwanarusk R, Ho ZZ, Chia A, Banu N, Howland SW, Ong ASM, Gehring AJ, Stauss H, Renia L, Sallberg M, Campana D, Bertoletti A (2013). A Practical Approach to Immunotherapy of Hepatocellular Carcinoma Using T Cells Redirected Against Hepatitis B Virus. MOLECULAR THERAPY-NUCLEIC ACIDS, 2, - . doi:10.1038/mtna.2013.43
    • Sassi A, Lazaroski S, Wu G, Haslam SM, Mellouli F, Patiroglu T, Jouhadi Z, Khadir K, Pfeifer D, Jakob T, Khemiri M, Ben-Mustapha I, Asplund C, Gustafsson M, Lundin K, Falk-Sorqvist E, Moens L, Unal E, Ozdemir MA, Gungor HE, Engelhardt K, Dziadzio M, Stauss H, Fleckenstein B, Fliegauf M, Meier R, Ben-Khemis L, Kraus H, Nadifi S, Eibel H, Nilsson M, Bejaoui M, Schaeffer A, Smith E, Dell A, Barbouche M-R, Grimbacher B (2013). Hypomorphic, Homozygous Mutations In Phosphoglucomutase-3 Impair Immunity And Increase Serum IgE Levels.
    • Qasim W, Brunetto M, Gehring A, Xue S-A, Zhan H, Ciccorossi P, Gilmour K, Cavallone D, Moriconi F, Farzhenah F, Mazzoni A, Chan L, Morris E, Thrasher A, Maini M, Bonino F, Stauss H, Bertoletti A (2013). THERAPY WITH T CELL RECEPTOR GENE MODIFIED T CELLS TARGETING HBsAg-PRODUCING HCC METASTASES.
    • Field A-C, Vink C, Gabriel R, Al-Subki R, Schmidt M, Goulden N, Stauss H, Thrasher A, Morris E, Qasim W (2013). Comparison of Lentiviral and Sleeping Beauty Mediated αβ T Cell Receptor Gene Transfer. PLoS ONE, 8(6), - .
    • Xue SA, Gao L, Ahmadi M, Ghorashian S, Barros RD, Pospori C, Holler A, Wright G, Thomas S, Topp M, Morris EC, Stauss HJ (2013). Human MHC Class I-restricted high avidity CD4(+) T cells generated by co-transfer of TCR and CD8 mediate efficient tumor rejection in vivo.. Oncoimmunology, 2(1), e22590 - . doi:10.4161/onci.22590
    • Griffin JE, Carpenter B, Nicholson E, Ghorashian S, Holler A, Velica P, Sivakumaran J, Pule M, Stauss H, Xue S, Chakraverty R (2013). Generation of mycophenolate mofetil-resistant T-cells to enable adoptive immunotherapy during immunosuppressive treatment.
    • Chan HW, Aslam A, Lee CH, Jones L, Wynne K, Wright G, Crack L, Macpherson T, Stauss H, Price DR, Ogg GS (2013). The role of Der p 1 specific T cells in atopic eczema. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 54, 13 - 14.
    • Alsubki R, Field A-C, Hirwarkar P, Saudemont A, Stauss H, Morris E, Thrasher A, Pule M, Qasim W (2013). Engineering cord blood T cells for tumour immunotherapy.
    • Carpenter BJM, Ghorashain S, Nicholson E, Griffin J, Ahmadi M, Zhang L, Flutter B, Holler A, Stauss H, Morris E, Chakraverty R (2013). Over-expression of CXCR4 targets donor T-cells to tumour niches and enhances graft-versus-lymphoma.
    • Stauss HJ, Morris EC (2013). Immunotherapy with gene-modified T cells: limiting side effects provides new challenges.. Gene Ther, , - . doi:10.1038/gt.2013.34
    • Stauss H (2013). Improving T cell therapy of cancer.

    2012

    • Gamez-Diaz L, Ehl S, Hauch H, Koscielniak E, Feuchtinger T, Speckmann C, Wanders J, Seneviratne S, Orange J, Enders A, Stauss H, Moustchen M, Eibel H, Grimbacher B (2012). NEW DEFICIENCY CAUSING EARLY-ONSET CVID: HOW TO DIAGNOSE LRBA DEFECTS?.
    • Chua I, Ahmadi M, Xue S, Holler A, Zamoyska R, Stauss HJ, Morris EC (2012). Exploiting CD8 co-receptor to improve the function of genetically modified CD4 T cells for cancer immunotherapy.
    • Lopez-Herrera G, Tampella G, Pan-Hammarstrom Q, Herholz P, Trujillo-Vargas CM, Phadwal K, Simon AK, Moutschen M, Etzioni A, Mory A, Srugo I, Melamed D, Hultenby K, Liu C, Baronio M, Vitali M, Philippet P, Dideberg V, Aghamohammadi A, Rezai N, Enright V, Du L, Salzer U, Eibel H, Pfeifer D, Veelken H, Stauss H, Lougaris V, Plebani A, Gertz EM, Schaeffer AA, Hammarstrom L, Grimbacher B (2012). DELETERIOUS LRBA MUTATIONS IN A NOVEL SYNDROME OF IMMUNE DEFICIENCY AND AUTOIMMUNITY.
    • Velica P, Zech M, Stauss H, Chakraverty R (2012). Turning mTOR down in TCR gene therapy: the path to long-term protection?.
    • Campbell M, Clarke A, Seneviratne S, Stauss H, Webster D (2012). 102 PSYCHOLOGICAL THERAPY FOR ADULTS WITH PRIMARY IMMUNODEFICIENCY.
    • Ghorashian S, Holler A, Carpenter B, Ahmadi M, Nicholson E, Zech M, Xue SA, Bennett C, Stauss HJ, Chakraverty R (2012). CD4 cells expressing an MHC class I restricted TCR can rescue CD8 cells tolerized to tumour-associated antigen.
    • Chiew M-L, Ballard S, Stauss H, Thrasher A, Longhurst H, Workman S (2012). WORLD IMMUNOLOGY DAY 2012 EDUCATIONAL SYMPOSIUM FOR CLINICIANS AND PATIENTS.
    • Carpenter B, Ghorashian S, Nicholson E, Griffin J, Ahmadi M, Zhang L, Holler A, Stauss H, Morris E, Chakraverty R (2012). Targeting therapeutic T cells to tumour niches.
    • Depner M, Wanders J, Stauss H, Jansson A, Dueckers G, Niehues T, Baumann U, Pedersen AS, Kilic SS, Atkinson TP, Puck JM, Franco JL, Devlin L, Jensen TD, Henderson P, Matthijs G, Ben Shoshan M, McCusker C, Jacob CM, Grimbacher B (2012). Gain-of-function mutations in STAT1: A new molecular cause for patients with chronic mucocutaneous candidiasis. MYCOSES, 55, 319 - 319.
    • Uttenthal BJ, Chua I, Morris EC, Stauss HJ (2012). Challenges in T cell receptor gene therapy.. J Gene Med, 14(6), 386 - 399. doi:10.1002/jgm.2637
    • Lopez-Herrera G, Tampella G, Pan-Hammarström Q, Herholz P, Trujillo-Vargas CM, Phadwal K, Simon AK, Moutschen M, Etzioni A, Mory A, Srugo I, Melamed D, Hultenby K, Liu C, Baronio M, Vitali M, Philippet P, Dideberg V, Aghamohammadi A, Rezaei N, Enright V, Du L, Salzer U, Eibel H, Pfeifer D, Veelken H, Stauss H, Lougaris V, Plebani A, Gertz EM, Schäffer AA, Hammarström L, Grimbacher B (2012). Deleterious mutations in LRBA are associated with a syndrome of immune deficiency and autoimmunity.. Am J Hum Genet, 90(6), 986 - 1001. doi:10.1016/j.ajhg.2012.04.015
    • Ghorashian S, Holler A, Flutter B, Xue S-A, Fallah-Arani F, Sivakumaran J, Bennett C, Morris E, Stauss HJ, Chakraverty R (2012). CD4 help can overcome tolerance developing in adoptively-transferred T cells transduced with a self-specific TCR.
    • Field A-C, Stauss HJ, Morris EC, Qasim W (2012). Comparison on lentiviral and Sleeping Beauty transposon-mediated gene expression of T cell receptor genes.
    • Zech M, Velica P, Holler A, Chakraverty R, Stauss H (2012). Manipulating mTOR to enhance T cell mediated tumour immunity in vivo.
    • Nicholson E, Ahmadi M, Thomas S, Holler A, Carpenter B, Xue SA, Stauss H, Morris E (2012). Enhancing the efficacy of T cell receptor (TCR) gene therapy by co-transfer of TCR and additional CD3 molecules into CD4+T cells.
    • Chua I, Xue SA, Holler A, Maniusyte R, Zamoyska R, Stauss HJ, Morris EC (2012). Exploiting CD8 beta mutations which increase TCR avidity to improve the function of genetically modified T cells for immunotherapy.
    • Lopez-Herrera G, Tampella G, Baronio M, Vitali M, Lougaris V, Plebani A, Pan-Hammarstroem Q, Hammarstroem L, Du L, Hultenby K, Trujillo-Vargas CM, Phadwal K, Simon AK, Moutschen M, Etzioni A, Srugo AMI, Melamed D, Liu C, Philippet P, Dideberg V, Aghamohammadi A, Rezai N, Enright V, Stauss H, Herholz P, Salzer U, Eibel H, Pfeifer D, Velkeen H, Gertz EM, Schaeffer AA, Grimbacher B (2012). Mutations in LRBA are Associated with a Syndrome of Immune Deficiency and Autoimmunity.
    • Nicholson E, Ghorashian S, Stauss H (2012). Improving TCR Gene Therapy for Treatment of Haematological Malignancies.. Adv Hematol, 2012, 404081 - . doi:10.1155/2012/404081
    • Nicholson EK, Ahmadi M, Holler A, Pike R, Carpenter B, Thomas S, Ghorashian S, Xue S-A, Stauss H, Morris E (2012). Enhancing the Efficacy of T Cell Receptor (TCR) Gene Therapy by Co-Transfer of TCR and Additional CD3 Molecules Into CD4+T Cells.
    • Nicholson EK, Ahmadi M, Holler A, Pike R, Carpenter B, Thomas S, Ghorashian S, Xue S-A, Stauss H, Morris E (2012). Enhancing the Efficacy of T Cell Receptor (TCR) Gene Therapy by Co-Transfer of TCR and Additional CD3 Molecules Into CD4+T Cells.
    • Depner M, van de Veerdonk F, Wanders J, Stauss H, Raabe J, Atkinson TP, Jr SHW, Niehues T, Dueckers G, Puck J, Stray-Pedersen A, Baumann U, Schmidt R, Franco JL, Orrego J, Ben-Shoshan M, McCusker C, Jacob CMA, Carneiro-Sampaio M, Devlin LA, Edgar JD, Gkrania-Klotsas E, Kumararatne D, Doffinger R, Henderson P, Russell RK, Dyrso T, Seneviratne SL, Matthijs G, Abinun M, Gennery A, Johnson M, van der Meer JWM, Netea MG, Lilic D, Grimbacher B (2012). MUTATION SCREENING IN STAT1, CARD9 AND PKC-DELTA IN PATIENTS WITH CHRONIC MUCOCUTANEOUS CANDIDIASIS.

    2011

    • Simpson AA, Mohammed F, Salim M, Tranter A, Rickinson AB, Stauss HJ, Moss PA, Steven NM, Willcox BE (2011). Structural and energetic evidence for highly peptide-specific tumor antigen targeting via allo-MHC restriction.. Proc Natl Acad Sci U S A, 108(52), 21176 - 21181. doi:10.1073/pnas.1108422109
    • King JW, Ahmadi M, Xue S, Voisine C, Holler A, Waxman J, Morris E, Stauss H (2011). Effect of CD3 on the efficacy of TCR gene therapy in vivo. JOURNAL OF CLINICAL ONCOLOGY, 29(15), - .
    • Nicholson E, Ahmadi M, Thomas S, Holler A, Carpenter B, Xue SA, Stauss H, Morris E (2011). Enhancing the efficacy of T cell receptor (TCR) gene therapy by co-transfer of TCR and additional CD3 molecules into CD4+T cells. HUM GENE THER, 22(10), A119 - A119.
    • Xue SA, Gao L, Ahmadi M, Ghorashian S, Pospori C, Holler A, Thomas S, Morris E, Stauss HJ (2011). Generation of MHC-I restricted CD4+CMV and EBV specific T cells for the management of leukaemia patients. HUM GENE THER, 22(10), A73 - A73.
    • Chua I, Holler A, Xue SHA, Zamoyska R, Stauss HJ, Morris EC (2011). T cells expressing genetically modified CDS co-receptor have enhanced T cell effector function. HUM GENE THER, 22(10), A34 - A35.
    • Ghorashian S, Nicholson E, Stauss HJ (2011). T cell gene-engineering to enhance GVT and suppress GVHD.. Best Pract Res Clin Haematol, 24(3), 421 - 433. doi:10.1016/j.beha.2011.05.004
    • Wright GP, Stauss HJ, Ehrenstein MR (2011). Therapeutic potential of Tregs to treat rheumatoid arthritis.. Semin Immunol, 23(3), 195 - 201. doi:10.1016/j.smim.2011.07.004
    • Xue S, Gao L, Ghorashian S, Pospori C, Ahmadi M, Holler A, Thomas S, Stauss HJ (2011). GENERATION OF MHC-I RESTRICTED CD4+CMV SPECIFIC T CELLS FOR THE MANAGEMENT OF LEUKEMIA PATIENTS. EXPERIMENTAL HEMATOLOGY, 39(8), S65 - S66.
    • Ahmadi M, King JW, Xue SA, Voisine C, Holler A, Wright GP, Waxman J, Morris E, Stauss HJ (2011). CD3 limits the efficacy of TCR gene therapy in vivo.. Blood, 118(13), 3528 - 3537. doi:10.1182/blood-2011-04-346338
    • Pospori C, Xue SA, Holler A, Voisine C, Perro M, King J, Fallah-Arani F, Flutter B, Chakraverty R, Stauss HJ, Morris EC (2011). Specificity for the tumor-associated self-antigen WT1 drives the development of fully functional memory T cells in the absence of vaccination. BLOOD, 117(25), 6813 - 6824. doi:10.1182/blood-2010-08-304568
    • Thomas S, Xue SA, Bangham CR, Jakobsen BK, Morris EC, Stauss HJ (2011). Human T cells expressing affinity-matured TCR display accelerated responses but fail to recognize low density of MHC-peptide antigen.. Blood, 118(2), 319 - 329. doi:10.1182/blood-2010-12-326736
    • Chan HW, Aslam A, Lee CH, Jones L, Wynne K, Wright G, Crack L, McPherson T, Stauss H, Price DR, Ogg GS (2011). Antigen dose and keratinocyte antigen presentation are specific determinants of T cell function in atopic eczema. AUSTRALAS J DERMATOL, 52, 19 - 20.
    • Alpizar YA, Chain B, Collins MK, Greenwood J, Katz D, Stauss HJ, Mitchison NA (2011). Ten years of progress in vaccination against cancer: the need to counteract cancer evasion by dual targeting in future therapies.. Cancer Immunol Immunother, 60(8), 1127 - 1135. doi:10.1007/s00262-011-0985-7
    • Cellerai C, Harari A, Stauss H, Yerly S, Geretti AM, Carroll A, Yee T, Ainsworth J, Williams I, Sweeney J, Freedman A, Johnson M, Pantaleo G, Kinloch-de Loes S (2011). Early and Prolonged Antiretroviral Therapy Is Associated with an HIV-1-Specific T-Cell Profile Comparable to That of Long-Term Non-Progressors. PLOS ONE, 6(4), - . doi:10.1371/journal.pone.0018164
    • Nicholson EK, Ahmadi M, Thomas S, Carpenter B, Voisine C, Xue S, Stauss HJ, Morris EC (2011). Improving the function of TCR gene modified T-cells for adoptive immunotherapy: co-transfer of additional CD3 molecules enhances functional avidity of TCR-transduced CD4+ T-cells.
    • Cellerai C, Harari A, Stauss H, Yerly S, Geretti AM, Carroll A, Yee T, Ainsworth J, Williams I, Sweeney J, Freedman A, Johnson M, Pantaleo G, Kinloch-de Loes S (2011). Prolonged antiretroviral therapy initiated at seroconversion is associated with a polyfunctional HIV-1-specific T-cell profile comparable to that of long-term non-progressors (LTNPs). HIV MED, 12, 11 - 11.
    • Wright GP, Ehrenstein MR, Stauss HJ (2011). Regulatory T-cell adoptive immunotherapy: potential for treatment of autoimmunity.. Expert Rev Clin Immunol, 7(2), 213 - 225. doi:10.1586/eci.10.96
    • Gehring AJ, Xue SA, Ho ZZ, Teoh D, Ruedl C, Chia A, Koh S, Lim SG, Maini MK, Stauss H, Bertoletti A (2011). Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines.. J Hepatol, 55(1), 103 - 110. doi:10.1016/j.jhep.2010.10.025
    • Ahmadi M, King J, Xue S-A, Voisine C, Holler A, Wright G, Waxman J, Morris E, Stauss H (2011). CD3 limits the efficacy of TCR gene therapy in vivo.

    2010

    • Thomas S, Stauss HJ, Morris EC (2010). Molecular immunology lessons from therapeutic T-cell receptor gene transfer. IMMUNOLOGY, 129(2), 170 - 177. doi:10.1111/j.1365-2567.2009.03227.x
    • Perro M, Tsang J, Xue SA, Escors D, Cesco-Gaspere M, Pospori C, Gao L, Hart D, Collins M, Stauss H, Morris EC (2010). Generation of multi-functional antigen-specific human T-cells by lentiviral TCR gene transfer.. Gene Ther, 17(6), 721 - 732. doi:10.1038/gt.2010.4
    • Ahmadi M, King J, Nicholson E, Xue SA, Morris E, Stauss H (2010). Co-transfer of CD3 molecules enhances the anti-tumour responses of TCR-transduced T cells.
    • Zech M, Holler A, Stauss H (2010). Overcoming tumour associated T cell inhibition by Indoleamine-2,3-dioxygenase and Arginase I.
    • Pospori C, Xue SA, Holler A, Stauss HJ (2010). Adoptive immunotherapy with TCR-transferred lymphocytes.
    • Xue SA, Ghorashian S, Pospori C, Ahmadi M, Holler A, Thomas S, Stauss HJ (2010). Development of CMV-specific T cells for the management of transplantation patients.
    • Ahmadi M, King J, Nicholson E, Morris E, Stauss H (2010). Enhancing the Efficacy of TCR Gene Therapy by Co-Transfer of CD3 Molecules.
    • Pospori C, Xue SA, Holler A, Voisine C, Perro M, Fallah-Arani F, Flutter B, Chakraverty R, Stauss HJ, Morris EC (2010). Specificity for a tumor-associated self-antigen drives the development of functional memory T cells in the absence of vaccination.
    • Morris EC, Martinez-Davila I, Cellerai C, Chen F, Moss P, Khwaja A, Virchis A, Kottaridis P, Stauss HJ (2010). WT1 peptide vaccination in poor risk adult AML patients induces WT1-specific immune responses: Results of a leukaemia research supported phase I clinical trial, WTPV-001.
    • Uttenthal BJ, Wright GP, Holler A, Stauss HJ, Chakraverty R, Ec M (2010). Adoptive Therapy with Redirected Antigen-Specific Primary Regulatory T Cells Is a Potential Novel Cellular Therapy for Graft-Versus-Host Disease.
    • Field AC, Stauss HJ, Goulden N, Morris E, Qasim W (2010). Defining an Optimal Promoter for Lentiviral Gene Expression of T Cell Receptor Genes.
    • Xue SA, Gao L, Pospori C, Ahmadi M, Holler A, Thomas S, Stauss HJ (2010). Development of Virus Specific T Cells for the Management of Leukaemia Patients.
    • Ahmadi M, King J, Nicholson E, Morris E, Stauss H (2010). Enhancing the Efficacy of TCR Gene Therapy by Co-Transfer of CD3 Molecules.
    • Chua I, Holler A, Zamoyska R, Stauss H, Morris E (2010). Improving T Cell Functional Avidity Through CD8 Co-Receptor Modification: A Novel Mechanism to Enhance TCR Gene Therapy.
    • Perro M, Tsang J, Xue SA, Escors D, Cesco-Gaspere M, Pospori D, Gao L, Hart D, Collins M, Stauss H, Morris EC (2010). Lentiviral Vectors for TCR Gene Transfer: Improved Function of TCR-Transduced T Cells After Non-Activating Cytokine-Mediated Transduction.
    • Wright GP, Notley CA, Uttenthal BJ, Xue SA, Ehrenstein MR, Stauss HJ (2010). Treating Immunopathology with Antigen-Specific Regulatory T Cells Generated by T Cell Receptor Gene Transfer.
    • Gehring AJ, Xue SA, Ho ZZ, Teoh DYL, Ruedl C, Chia A, Koh S, Lim SG, Maini MK, Stauss H, Bertoletti A (2010). ENGINEERING VIRUS-SPECIFIC T CELL IMMUNITY TO TARGET CHRONIC HEPATITIS B VIRUS INFECTION AND HBV-RELATED HEPATOCELLULAR CARCINOMA.

    2009

    • Wright GP, Notley CA, Xue SA, Bendle GM, Holler A, Schumacher TN, Ehrenstein MR, Stauss HJ (2009). Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis.. Proc Natl Acad Sci U S A, 106(45), 19078 - 19083. doi:10.1073/pnas.0907396106
    • Dai MS, Nitcheu-Tefit J, Alcock S, Ramirez-Jimenez F, Chao TY, Baril P, Rocha M, Brett SJ, Stauss HJ, Vassaux G (2009). Development of an Escherichia coli expressing listeriolysin-O vaccine against Wilms tumor gene 1-expressing tumors.. J Immunother, 32(8), 845 - 855. doi:10.1097/CJI.0b013e3181aee259
    • Pospori C, Cesco-Gaspere M, Xue S, Voisine C, Perro M, Holler A, Wright G, Stauss H, Morris E (2009). WT1-TCR gene transfer into haematopoietic stem cells: a tumour immunotherapy model.
    • King JW, Thomas S, Corsi F, Gao L, Dina R, Gillmore R, Pigott K, Kaisary A, Stauss HJ, Waxman J (2009). IL15 can reverse the unresponsiveness of Wilms' tumor antigen-specific CTL in patients with prostate cancer.. Clin Cancer Res, 15(4), 1145 - 1154. doi:10.1158/1078-0432.CCR-08-1821
    • Kinloch S, Cellerai C, Yerly S, Byrne P, Carroll A, Stauss H, Johnson A, Harari A, Pantaleo G (2009). Immunologic and virologic characterization of an ART-treated HIV-I patients cohort with long-term control of viremia. RETROVIROLOGY, 6, - .
    • Cesco-Gaspere M, Morris E, Stauss HJ (2009). Immunomodulation in the treatment of haematological malignancies. Clinical and Experimental Medicine, 9(2), 81 - 92.
    • Pospori C, Cesco-Gaspere M, Xue S, Voisine C, Perro M, Holler A, Wright G, Stauss H, Morris E (2009). WT1-TCR gene transfer into HSCs: a tumour immunotherapy model.

    2008

    • Dunleavy A, Smith CJ, Breen RAM, Stauss HJ, Lipman MCI (2008). DISTINCT CD4 T-CELL DIFFERENTIATION MARKERS ARE PRESENT IN THE LUNGS OF SUBJECTS WITH ACTIVE TUBERCULOSIS.
    • Buchan SL, Chaise C, Rice J, Marquet J, Rouard H, Kuentz M, Vittes GE, Molinier-Frenkel V, Farcet JP, Stauss HJ, Delfau-Larue MH, Stevenson FK (2008). DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance.
    • Dunleavy A, Breen RAM, Stauss HJ, Lipman MCI (2008). TREATMENT-RELATED TUBERCULOSIS PARADOXICAL REACTIONS ARE ASSOCIATED WITH INCREASES IN ANTIGEN-SPECIFIC MYCOBACTERIAL RESPONSES IN THE LUNG.
    • Chaise C, Buchan SL, Rice J, Marquet J, Rouard H, Kuentz M, Vittes GE, Molinier-Frenkel V, Farcet JP, Stauss HJ, Delfau-Larue MH, Stevenson FK (2008). DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance.. Blood, 112(7), 2956 - 2964. doi:10.1182/blood-2008-02-137695
    • King J, Waxman J, Stauss H (2008). Advances in tumour immunotherapy.. QJM, 101(9), 675 - 683. doi:10.1093/qjmed/hcn050
    • Perro M, Xue SA, Tsang J, Cesco-Gaspere M, Escors D, Collins M, Morris E, Stauss H (2008). Lentiviral TCR gene transfer for adoptive immunotherapy of cancer.
    • Stauss HJ, Thomas S, Cesco-Gaspere M, Hart DP, Xue SA, Holler A, King J, Wright G, Perro M, Pospori C, Morris E (2008). WT1-specific T cell receptor gene therapy: Improving TCR function in transduced T cells. Blood Cells, Molecules, and Diseases, 40(1), 113 - 116. doi:10.1016/j.bcmd.2007.06.018
    • Gehring AJ, Xue SA, Lim SG, Maini MK, Stauss H, Bertoletti A (2008). Reconstitution of HBV specific immunity via retroviral gene transfer of a HBV core specific T cell receptor in chronic hepatitis B patients.
    • Tsang JY, Tanriver Y, Jiang S, Xue SA, Ratnasothy K, Chen D, Stauss HJ, Bucy RP, Lombardi G, Lechler R (2008). Conferring indirect allospecificity on CD4+CD25+ Tregs by TCR gene transfer favors transplantation tolerance in mice. Journal of Clinical Investigation, 118(11), 3619 - 3628. doi:10.1172/JCI33185
    • Leisegang M, Engels B, Meyerhuber P, Kieback E, Sommermeyer D, Xue SA, Reuss S, Stauss H, Uckert W (2008). Enhanced functionality of T cell receptor-redirected T cells is defined by the transgene cassette.. Journal of Molecular Medicine, 86(5), 573 - 583. doi:10.1007/s00109-008-0317-3
    • King J, Dina R, Waxman J, Stauss H (2008). Evaluating the Wilms' tumour antigen 1 as a target for the immunotherapy of prostate cancer. doi:10.1016/j.ctrv.2008.03.114
    • Xue SA, Bendle GM, Holler A, Stauss HJ (2008). Generation and characterization of transgenic mice expressing a T-cell receptor specific for the tumour-associated antigen MDM2. Immunology, 124(3), 315 - 321. doi:10.1111/j.1365-2567.2007.02793.x
    • Hart DP, Xue SA, Thomas S, Cesco-Gaspere M, Tranter A, Willcox B, Lee SP, Steven N, Morris EC, Stauss HJ (2008). Retroviral transfer of a dominant TCR prevents surface expression of a large proportion of the endogenous TCR repertoire in human T cells.. Gene Therapy, 15(8), 625 - 631. doi:10.1038/sj.gt.3303078
    • Hart DP, Thomas S, Xue S, Stauss HJ, Morris EC (2008). LMP2-specific TCR gene therapy for Hodgkin's lymphoma.

    2007

    • Tamir A, Basagila E, Kagahzian A, Jiao L, Jensen S, Nicholls J, Tate P, Stamp G, Farzaneh F, Harrison P, Stauss H, George AJ, Habib N, Lechler RI, Lombardi G (2007). Induction of tumor-specific T-cell responses by vaccination with tumor lysate-loaded dendritic cells in colorectal cancer patients with carcinoembryonic-antigen positive tumors.. Cancer Immunol Immunother, 56(12), 2003 - 2016. doi:10.1007/s00262-007-0299-y
    • Hart DP, Thomas S, Xue SA, Morris EC, Stauss HJ (2007). LMP2-specific TCR gene therapy for Hodgkin lymphoma - Design of a dominant TCR construct for immunotherapy.
    • Nitcheu-Tefit J, Dai MS, Critchley-Thorne RJ, Ramirez-Jimenez F, Xu M, Conchon S, Ferry N, Stauss HJ, Vassaux G (2007). Listeriolysin O expressed in a bacterial vaccine suppresses CD4+CD25high regulatory T cell function in vivo.. J Immunol, 179(3), 1532 - 1541.
    • McNicol AM, Bendle G, Holler A, Matjeka T, Dalton E, Rettig L, Zamoyska R, Uckert W, Xue SA, Stauss HJ (2007). CD8alpha/alpha homodimers fail to function as co-receptor for a CD8-dependent TCR.. Eur J Immunol, 37(6), 1634 - 1641. doi:10.1002/eji.200636900
    • Tsang JYS, Jiang S, Tanriver Y, Xue SA, Stauss H, Bucy RP, Lombardi G, Lechler R (2007). Generation of CD4+CD25+ regulatory T cells with indirect alloresponses by T cell receptor gene transfer: A novel therapeutic agent for the induction of transplantation tolerance..
    • Nitcheu-Tefit J, Dai MS, Critchley-Thorne RJ, Ramirez-Jimenez F, Xu M, Conchon S, Ferry N, Stauss HJ, Vassaux G (2007). Listeriolysin-O expressed in a bacterial vaccine inhibits Treg cells function in vivo.
    • Thomas S, Hart DP, Xue SA, Cesco-Gaspere M, Stauss HJ (2007). T-cell receptor gene therapy for cancer: the progress to date and future objectives.. Expert Opinion on Biological Therapy, 7(8), 1207 - 1218.
    • Bendle GM, Xue SA, Holler A, Stauss HJ (2007). A study of T cell tolerance to the tumor-associated antigen MDM2: cytokines can restore antigen responsiveness, but not high avidity T cell function. PLoS One, 2(4), e353 - . doi:10.1371/journal.pone.0000353
    • Xue SA, Stauss HJ (2007). Enhancing immune responses for cancer therapy.. Cellular and Molecular Immunology, 4(3), 173 - 184.
    • Morris E, Hart DP, King J, Thomas S, Cesco-Gaspere M, Xue SA, Stauss HJ (2007). Immunotherapy of Leukaemia with TCR gene modified T cells. Hematology Education: The education program for the annual congress of the European Hematology Association, 1(1), 264 - 268.
    • Stauss HJ, Cesco-Gaspere M, Thomas S, Hart DP, Xue SA, Holler A, Wright G, Perro M, Little AM, Pospori C, King J, Morris EC (2007). Monoclonal T-cell receptors: new reagents for cancer therapy. Molecular Therapy, 15(10), 1744 - 1750.
    • Thomas S, Xue SA, Cesco-Gaspere M, San Jose E, Hart D, Morris E, Stauss H (2007). Targeting the Wilms Tumour antigen 1 by TCR gene transfer: TCR variants improve tetramer binding but not the function of gene modified human T cells. The Journal of Immunology, 179(9), 5803 - 5810.
    • Ramírez F, Ghani Y, Gao L, Stauss H (2007). Dendritic cell immunization induces Nonprotective WT1-specific CTL responses in mouse.. J Immunother, 30(2), 140 - 149. doi:10.1097/01.cji.0000211328.76266.81

    2006

    • Morris E, Hart D, Gao LQ, Tsallios A, Xue SA, Stauss H (2006). Generation of tumor-specific T-cell therapies. BLOOD REV, 20(2), 61 - 69. doi:10.1016/j.blre.2005.05.001
    • Morris E, Hart D, Gao L, Tsallios A, Xue SA, Stauss H (2006). Generation of tumor-specific T cell therapies. Blood Reviews, , - .
    • Gillmore R, Xue SA, Holler A, Kaeda J, Hadjiminas D, Healy V, Dina R, Parry SC, Bellantunon I, Ghani Y, Coombes RC, Waxman J, Stauss HJ (2006). Detection of Wilms' tumour antigen-specific CTL in tumor draining lymph nodes of patients with early breast cancer. Clinical Cancer Research, 12(1), 34 - 42.

    2005

    • Bendle GM, Holler A, Xue S, Stauss HJ (2005). TCR transgenic mice reveal the magnitude and mechanisms of CD8+T cell tolerance to the broadly expressed tumour-associated protein MDM2. IMMUNOLOGY, 116, 16 - 17.
    • Keilholz U, Menssen HD, Gaiger A, Menke A, Oji Y, Oka Y, Scheibenbogen C, Stauss H, Thiel E, Sugiyama H (2005). Wilms' tumour gene 1 (WT1) in human neoplasia. Leukemia, 19(8), 1318 - 1323.
    • Hart DP, Morris EC, Stauss HJ (2005). Effect of Interleukin 15 on human, antigen-specific CD8+T cells.
    • Morris EC, Tsallios A, Bendle G, Xue S, Stauss HJ (2005). Functional analysis of TCR-transduced MHC class I-restricted helper T cells and their role in tumor protection. IMMUNOLOGY, 116, 32 - 32.
    • Xue SA, Gao LQ, Hart D, Gillmore R, Qasim W, Thrasher A, Apperley J, Engels B, Uckert W, Morris E, Stauss H (2005). Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. BLOOD, 106(9), 3062 - 3067. doi:10.1182/blood-2005-01-0146
    • Bendle GM, Xue S, Holler A, Stauss HJ (2005). A transgenic model reveals the mechanisms and magnitude of CD8+T cell tolerance to the broadly expressed tumor-associated protein MDM2.
    • Gillmore R, Xue S, Holler A, Kaeda J, Hadjiminas D, Healy V, Ghani Y, Coombes RC, Waxman J, Stauss HJ (2005). Cytotoxic T cells specific for the Wilms' tumor protein are present in patients with breast cancer and are of sufficient avidity to kill breast cancer cells.
    • Xue S, Gao L, Hart D, Gillmore R, Qasime W, Thrasher A, Uckert W, Morris E, Stauss H (2005). Development of WT1-specific CTL for the treatment of human leukemia through TCR gene transfer.
    • Hart DP, Morris EC, Stauss HJ (2005). Effect of interleukin 15 supplementation on peptide-specific expansion of human T cells.
    • Ramirez F, Ghani Y, Stauss H (2005). Immunogenicity of the tumour associated antigen WT1.
    • Tsallios A, Stauss HJ, Morris EC (2005). MHC class 1-restricted CD4+ helper T cells augment CD8+ cytotoxic T cell mediated anti-tumour immunity.
    • Downs AM, Bendle G, Dalton E, Rettig L, Zamoyska R, Xue SA, Stauss HJ (2005). TCR gene transfer to analyse the role of CD8 in tumour-reactive cytotoxic T-cells.
    • Van Driessche A, Ponsaerts P, Nijs G, Lenjou M, Gao L, Van Bockstaele DR, Stauss HJ, Van Tendeloo VFI, Berneman ZN (2005). Wilms' tumor antigen-1 (WT1) presentation and specific T cell-priming by human dendritic cells electroporated with WT1 mRNA.
    • Morris EC, Tsallios A, Bendle GM, Xue SA, Stauss HJ (2005). A critical role for TCR-transduced MHC class I-restricted helper T cells in long-term tumor protection.. Proceedings of the National Academy of Sciences of the United States of America, 102(22), 7934 - 7939. doi:10.1073/pnas.0500357102
    • Tsallios A, Stauss HJ, Morris EC (2005). A critical role of gene-modified MHC class I-restricted helper T cells in long-term tumour protection.
    • Tan PH, Herrera OB, Yates J, Harper JE, Watson MP, Chan C, Xue SA, Jordan WJ, Dong R, Stauss HJ, Ritter MA, Lechler RI, Lombardi G, George AJT (2005). Creation of tolerogenic antigen presenting cells via intracellular CTLA4: a novel strategy with potential clinical utility in transplantation.
    • Tan PH, Xue SA, Wang YH, Beutelspacher SC, McAlister JC, Larkin DFP, McClure MO, Stauss HJ, Ritter MA, Lombardi G, George AJT (2005). Modulation of human dendritic cell function following viral vectors: implications for gene therapy in vaccination.
    • Van Driessche A, Gao L, Stauss HJ, Ponsaerts P, Van Bockstaele DR, Berneman ZN, Van Tendeloo VF (2005). Antigen-specific cellular immunotherapy of leukemia. Leukemia, 19(11), 1863 - 1871.
    • Bendle GM, Holler A, Downs A-M, Xue SA, Stauss HJ (2005). Broadly expressed tumour-associated proteins as targets for cytotoxic T lymphocyte-based cancer immunotherapy. Expert Opinion on Biological Therapy, 5(9), 1183 - 1192.
    • Xue SA, Gao LQ, Hart D, Gillmore R, Qasim W, Thrasher A, Apperley J, Engels B, Uckert W, Morris E, Stauss H (2005). Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. Blood, 106(9), 3062 - 3067. doi:10.1182/blood-2005-01-0146
    • Xue S, Gillmore R, Downs A, Tsallios A, Holler A, Gao L, Wong E, Morris E, Stauss HJ (2005). Exploiting T cell receptor genes for cancer immunotherapy. Clinical and Experimental Immunology, 139, 167 - 172.
    • Morris E, Hart D, Tsallios A, Xue SA, Stauss HJ (2005). Generation of tumour-specific T-cell therapies. Blood Reviews, (June 21), - .
    • Gao L, Downs A-M, Stauss HJ (2005). Immunotherapy with CTL restricted by non-self MHC. Methods of Molecular Medicine, 109, 215 - 228.
    • Tan PH, Beutelspacher SC, Xue SA, Wang YH, Mitchell P, McAlister JC, Larkin DF, McClure MO, Stauss HJ, Ritter MA, Lombardi G, George AJ (2005). Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy. Blood, 105(10), 3824 - 3832.
    • Chai JG, Xue SA, Coe D, ddey C, Bartok I, Scott D, Simpson E, Stauss HJ, Hori S, Sakaguchi S, Dyson J (2005). Regulatory T cells derived from naive CD4+CD25- T cells by in vitro Foxp3 gene transfer can induce tranplantation tolerance. Transplantation, 79(10), 1310 - 1316.
    • Ghaem-Maghami S, Nikolakopoulou Z, Gabra H, Stauss H (2005). WT1 as a target for immunotherapy inovarian cancer. IMMUNOLOGY, 116, 40 - 40.

    2004

    • Ramírez F, Ghani Y, Stauss H (2004). Incomplete tolerance to the tumour-associated antigen MDM2.. Int Immunol, 16(2), 327 - 334.
    • Stauss HJ, Xue S, Gillmore R, Gao L, Bendle G, Holler A, Downs AM, Morris E (2004). Exploiting alloreactivity for tumour immunotherapy.. Vox Sanguinis, 87(suppl 2), 227 - 229.
    • Liang HD, Lu QL, Xue SA, Halliwell M, Kodoma T, Cosgrove DO, Stauss HJ, Partridge TA, Blomley MJ (2004). Optimisation of ultrasound medidated gene transfer (sonoporation) in skeletal muscle cells. Ultrasound in Medicine and Biology, 30(11), 1523 - 1529.
    • Xue S, Gillmore R, Gao L, Bendle G, Holler A, Downs AM, Tsallios A, Ramirez F, Ghani Y, Hart D, Alcock S, Tranter A, Morris E, Stauss HJ (2004). Use of the allogeneic repertoire to enhance anti-tumor immunity.. Journal of Biological Regulators and Homeostatic Agents, 18(1), 131 - 133.
    • Xue S, Gao L, Gillmore R, Bendle G, Holler A, Downs AM, Tsallios A, Ramirez F, Ghani Y, Hart D, Alcock S, Tranter A, Stauss HJ, Morris E (2004). WT1-targeted immunotherapy of leukaemia.. Blood Cells, Molecules, and Diseases, 33(3), 288 - 290.
    • Xue S, Gao L, Morris E, Gillmore R, Stauss H (2004). WT1-targeted immunotherapy of leukemia..
    • Tsallios A, Xue S, Stauss HJ, Morris EC (2004). CD8-independent, MHC class I-restricted antigen recognition by murine CD4 T cells via transferred T-cell receptors.
    • Berneman ZN, Van Driessche A, Ponsaerts P, Gao LQ, Stauss HJ, Schroyens WA, Van de Velde A, Gadisseur A, Lenjou M, Nijs G, Van Bockstaele DR, Van Tendeloo VF (2004). Immunotargetting of the Wilms' tumor WT1 antigen for dendritic cell and B-cell-based vaccination of leukemia..
    • Morris E, Tsallios A, Bendle G, Xue SA, Stauss H (2004). T cell receptor gene transfer to produce MHC class I-restricted CD4 helper T cells: Implications for immunotherapy of leukaemia.
    • Bendle G, Holler A, Pang L, Hsu S, Krampera M, Simpson E, Sadovnikova E, Stauss HJ (2004). Induction of unresponsiveness limits tumour protection by adoptively transferred MDM2-specific cytotoxic T lymphocytes. Cancer Research, 64(21), 8052 - 8056.
    • Savage P, Gao L, Vento K, Cowburn P, Man S, Steven N, Ogg G, McMichael A, Epenetos A, Goulmy E, Stauss HJ (2004). Use of B-cell bound HLA-A2 class i monomers to generate high avididty, allo-restricted CTL against the leukaemia-associated protein Wilms tumour antigen 1. Blood, 103(12), 4613 - 4615. doi:10.1182/blood-2003-11-3903
    • Van Driessche A, Ponsaerts P, Nijs G, Lenjou M, Gao LQ, Stauss HJ, Berneman Z, Van Bockstaele DR, Van Tendeloo V (2004). Wilms' tumor (WT1) antigen loading of dendritic cells using MRNA electroporation for preclinical leukemia vaccine development.
    • Nitcheu J, Ramirez-Jimenez FS, Stauss HJ, Vassaux G, Young BD (2004). Escherichia coli expressing recombinant WT1 protein and listeriolysin O stimulate antigen-specific T cells following vaccination in C57BL/6 mice..

    2003

    • Gao LQ, Xue SA, Hasserjian R, Cotter F, Kaeda J, Goldman JM, Dazzi F, Stauss HJ (2003). Human cytotoxic T lymphocytes specific for Wilms' tumor antigen-1 inhibit engraftment of leukemiainitiating stem cells in non-obese diabetic-severe combined immunodeficient recipients. TRANSPLANTATION, 75(9), 1429 - 1436. doi:10.1097/01.TP.0000061516.57346
    • Gao L, Xue SA, Hasserjian R, Cotter F, Kaeda J, Goldman JM, Dazzi F, Stauss HJ (2003). Human cytotoxic T lymphocytes specific for Wilms' tumor antigen-1 inhibit engraftment of leukemia-initiating stem cells in non-obese diabetic-severe combined immunodeficient recipients.. Transplantation, 75(9), 1429 - 1436. doi:10.1097/01.TP.0000061516.57346.E8
    • Gao L, Xue S, Hasserijan R, Cotter F, Kaeda J, Goldman JM, Dazzi F, Stauss HJ (2003). Human cytotoxic T-lymphocytes specific for Wilms tumor antigen-1 inhibit engraftment of leukemia-initiating stem cells in NOD/SCID recipients. Transplantation, 75, 1429 - 1436.
    • Amrolia PJ, Reid SD, Gao L, Schultheis B, Dotti G, Brenner MK, Melo JV, Goldman JM, Stauss HJ (2003). Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity. Blood, 101(3), 1007 - 1014. doi:10.1182/blood-2002-02-0525
    • Morris EC, Bendle GM, Stauss HJ (2003). Prospects for immunotherapy of malignant disease. Clin Exp Immunol, 131, 1 - 7.
    • Stauss HJ, Bellantuono I, Hsu SC, Ramirez F (2003). Tumour Immunology. In Lightstone E, Friedland J (Ed.), Infection and Immunity (pp. - ). : Martin Dunitz.
    • Stauss HJ, Xue S, Gao L, Bendle G, Holler A, Gillmore R, Ramirez F (2003). WT1 as target for tumor immunotherapy. In Stauss HJ, Parmiani G, Kawakmi Y (Ed.), Tumour antigens recognised by T cells and antibodies (pp. - ). : Harwood Academic Publishers.
    • Ramirez F, Ghani Y, Stauss HJ (2003). Incomplete tolerance to the tumour-associated antigen MDM2. International Immunology, 16(2), 327 - 334.

    2002

    • Yang TH, Lovatt M, Merkenschlager M, Stauss HJ (2002). Comparison of the frequency of peptide-specific cytotoxic T lymphocytes restricted by self- and allo-MHC following in vitro T cell priming.. Int Immunol, 14(11), 1283 - 1290.
    • Bellantuono I, Gao L, Parry S, Marley S, Dazzi F, Apperley J, Goldman JM, Stauss HJ (2002). Two distinct HLA-A0201-presented epitopes of the Wilms Tumor Antigen 1 can function as targets for leukemia-reactive CTL. Blood, 100(10), 3835 - 3837.
    • Sadovnikova E, Parovichnikova EN, Savchenko VG, Zabotina T, Stauss HJ (2002). The CD68 protein as a potential target for leukaemia-reactive CTL. Leukemia, 16(10), 2019 - 2026.
    • Yang TH, Lovatt M, Merkenschlager M, Stauss HJ (2002). Comparison of the freqency of peptide-specific CTL restricted by self and allo-MHC following in vitro T cell priming. International Immunology, 14(11), 1283 - 1290.

    2001

    • Stauss HJ (2001). Benign autoimmunity to combat malignancy.. Clin Exp Immunol, 125(1), 1 - 2.
    • Stanislawski T, Voss RH, Lotz C, Sadovnikova E, Willemsen RA, Kuball J, Ruppert T, Bolhuis RL, Melief CJ, Huber C, Stauss HJ, Theobald M (2001). Circumventing tolerance to a human MDM2-derived tumour antigen by TCR gene transfer. Nature Immunology, 2(10), 962 - 970. doi:10.1038/ni1001-962

    2000

    • Amrolia PJ, Gao L, Reid SD, Goldman JM, Stauss HJ (2000). Allorestricted cytotoxic T-cells specific for human CD45 show potent anti-leukemic activity.. BLOOD, 96(11), 551A - +.
    • Bellantuono I, Macchiarulo E, Gao LQ, Dazzi F, Cerundolo V, Marley SB, Gordon MY, Goldman JM, Stauss HJ (2000). Immunoresponse to Wilms Tumor antigen-1 (WT-1) in CML patients.. BLOOD, 96(11), 144A - 144A.
    • Dazzi F, Chandler P, Dewchand H, Millrain M, Laylor R, Picard J, Stauss H, Goldman J, Simpson E (2000). The host-versus-graft (HvG) reaction in allogeneic stem cell transplantation (SCT): Donor-recipient chimerism is not associated with clonal deletion of HvG effector T cells.. BLOOD, 96(11), 374A - 374A.
    • Marelli-Berg FM, Peek E, Lidington EA, Stauss HJ, Lechler RI (2000). Isolation of endothelial cells from murine tissue.. J Immunol Methods, 244(1-2), 205 - 215.
    • Perraudeau M, Taylor PR, Stauss HJ, Lindstedt R, Bygrave AE, Pappin DJ, Ellmerich S, Whitten A, Rahman D, Canas B, Walport MJ, Botto M, Altmann DM (2000). Altered major histocompatibility complex class II peptide loading in H2-O-deficient mice.. Eur J Immunol, 30(10), 2871 - 2880. doi:10.1002/1521-4141(200010)30:10<2871::AID-IMMU2871>3.0.CO;2-B
    • Gao L, Bellantuono I, Elsässer A, Marley SB, Gordon MY, Goldman JM, Stauss HJ (2000). Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1.. Blood, 95(7), 2198 - 2203.
    • Lovatt M, Yang TH, Stauss HJ, Fisher AG, Merkenschlager M (2000). Different doses of agonistic ligand drive the maturation of functional CD4 and CD8 T cells from immature precursors.. Eur J Immunol, 30(2), 371 - 381. doi:10.1002/1521-4141(200002)30:2<371::AID-IMMU371>3.0.CO;2-T

    1999

    • Gao L, Yang TH, Tourdot S, Sadovnikova E, Hasserjian R, Stauss HJ (1999). Allo-major histocompatibility complex-restricted cytotoxic T lymphocytes engraft in bone marrow transplant recipients without causing graft-versus-host disease.. Blood, 94(9), 2999 - 3006.
    • Bellantuono I, Gao L, Elsaesser A, Marley S, Gordon M, Goldman J, Stauss H (1999). Selective elimination of leukemic progenitors by allorestricted CTL specific for Wilms tumor antigen-1 (WT-1).. BLOOD, 94(10), 532A - 533A.
    • Aosai F, Mun HS, Norose K, Chen M, Hata H, Kobayashi M, Kiuchi M, Stauss HJ, Yano A (1999). Protective immunity induced by vaccination with SAG1 gene-transfected cells against Toxoplasma gondii-infection in mice.. Microbiol Immunol, 43(1), 87 - 91.
    • Stauss HJ (1999). Immunotherapy with CTLs restricted by nonself MHC.. Immunol Today, 20(4), 180 - 183.

    1998

    1997

    • Alamartine E, Stauss HJ, Beverley PCL (1997). Both ICAM-1 and B7.1 are required to convert non-stimulatory keratinocytes into T cell-stimulating APCs. EUR J DERMATOL, 7(7), 481 - 486.
    • Cotterill LA, Stauss HJ, Millrain MM, Pappin DJ, Rahman D, Canas B, Chandler P, Stackpoole A, Simpson E, Robinson PJ, Dyson PJ (1997). Qa-1 interaction and T cell recognition of the Qa-1 determinant modifier peptide.. Eur J Immunol, 27(9), 2123 - 2132. doi:10.1002/eji.1830270902
    • Stauss HJ, Dahl M, Sadovnikova E (1997). Tumour-reactive cytotoxic T-lymphocytes specific for normal cellular proteins.. Biochem Soc Trans, 25(2), 540 - 543.
    • Zhu X, Stauss HJ, Ivanyi J, Vordermeier HM (1997). Specificity of CD8+ T cells from subunit-vaccinated and infected H-2b mice recognizing the 38 kDa antigen of Mycobacterium tuberculosis.. Int Immunol, 9(11), 1669 - 1676.

    1996

    • Lechler R, Hargreaves R, Bobek G, Lombardi G, Stauss H, Lightstone L (1996). In the absence of Ii, MHC class II molecules display a distinct set of self peptides. HUMAN IMMUNOLOGY, 47(1-2), O71 - O71.
    • Sadovnikova E, Stauss HJ (1996). Cytotoxic T lymphocytes against peptides derived from cyclin D1 isolated from peripheral blood of normal individuals.. HUM IMMUNOL, 47(1-2), P95 - P95.
    • Dahl AM, Beverley PCL, Stauss HJ (1996). A synthetic peptide derived from the tumor-associated protein mdm2 can stimulate autoreactive, high avidity cytotoxic T lymphocytes that recognize naturally processed protein. J IMMUNOL, 157(1), 239 - 246.
    • McCormick D, Stauss HJ, Thorpe C, Travers P, Dyson PJ (1996). Major histocompatibility complex and T cell receptor interaction of the P91A tum- peptide.. Eur J Immunol, 26(12), 2895 - 2902. doi:10.1002/eji.1830261214
    • Sadovnikova E, Stauss HJ (1996). Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy.. Proc Natl Acad Sci U S A, 93(23), 13114 - 13118.

    1995

    • CHAIN BM, GAO LQ, TRAVERS P, STAUSS H (1995). CTL EPITOPES WITHIN THE HUMAN PAPILLOMA-VIRUS E6 PROTEIN. J CELL BIOCHEM, , 289 - 289.
    • Stauss HJ (1995). Mutant Ras proteins and peptides: bad news for tumors.. J Natl Cancer Inst, 87(24), 1820 - 1822.
    • ZHU X, TOMMASINO M, VOUSDEN K, SADOVNIKAVA E, RAPPUOLI R, CRAWFORD L, KAST M, MELIEF CJM, BEVERLEY PCL, STAUSS HJ (1995). BOTH IMMUNIZATION WITH PROTEIN AND RECOMBINANT VACCINIA VIRUS CAN STIMULATE CTL SPECIFIC FOR THE E7 PROTEIN OF HUMAN-PAPILLOMA-VIRUS-16 IN H-2(D) MICE. SCAND J IMMUNOL, 42(5), 557 - 563.
    • LIGHTSTONE L, BOBEK G, PETERSON M, LOMBARDI G, STAUSS H, LECHLER R (1995). THE INFLUENCE OF AN INFLAMMATORY MILIEU ON ANTIGEN PRESENTATION - A POSSIBLE ROUTE TO AUTOIMMUNITY. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 6(3), 840 - 840.
    • Gao L, Walter J, Travers P, Stauss H, Chain BM (1995). Tumor-associated E6 protein of human papillomavirus type 16 contains an unusual H-2Kb-restricted cytotoxic T cell epitope.. J Immunol, 155(12), 5519 - 5526.

    1994

    • ZHU X, SADOVNIKOVA E, COLLINS S, THOMAS C, STAUSS H, VOUSDEN K, CRAWFORD L, BEVERLEY P (1994). MAPPING OF MURINE CTL EPITOPES IN HPV-16 E7. JOURNAL OF CELLULAR BIOCHEMISTRY, , 295 - 295.
    • Gao L, Chain B, Sinclair C, Crawford L, Zhou J, Morris J, Zhu X, Stauss H (1994). Immune response to human papillomavirus type 16 E6 gene in a live vaccinia vector.. J Gen Virol, 75 ( Pt 1), 157 - 164.
    • Sadovnikova E, Zhu X, Collins SM, Zhou J, Vousden K, Crawford L, Beverley P, Stauss HJ (1994). Limitations of predictive motifs revealed by cytotoxic T lymphocyte epitope mapping of the human papilloma virus E7 protein.. Int Immunol, 6(2), 289 - 296.
    • Sadovnikova E, Stauss HJ (1994). T cell epitopes in human papilloma virus proteins.. Behring Inst Mitt, (94), 87 - 93.
    • GAO LQ, CHAIN B, SINCLAIR C, SADOVNIKOVA E, STAUSS HJ, ZHU XJ, BEVERLEY PCL, CRAWFORD L, ZHOU J (1994). T-CELL EPITOPE MAPPING IN HUMAN PAPILLOMAVIRUS TYPE-16 E6 ONCOPROTEIN.
    • BEVERLEY PCL, SADOVNIKOVA E, ZHU X, HICKLING J, GAO L, CHAIN B, COLLINS S, CRAWFORD L, VOUSDEN K, STAUSS HJ (1994). STRATEGIES FOR STUDYING MOUSE AND HUMAN IMMUNE-RESPONSES TO HUMAN PAPILLOMAVIRUS TYPE-16.
    • Yin L, Thomas C, Hsuan JJ, Stauss HJ (1994). Unconventional cytotoxic T lymphocyte recognition of synthetic peptides corresponding to residues 1-23 of Ras protein. European Journal of Immunology, 24(9), 1988 - 1992.

    1993

    • SKIPPER J, STAUSS H (1993). RECOGNITION OF RAS PEPTIDES BY CLASS-I RESTRICTED T-CELLS. JOURNAL OF CELLULAR BIOCHEMISTRY, , 112 - 112.
    • Skipper J, Stauss HJ (1993). Identification of two cytotoxic T lymphocyte-recognized epitopes in the Ras protein.. J Exp Med, 177(5), 1493 - 1498.
    • Koeppen HK, Singh S, Stauss HJ, Park BH, Rowley DA, Schreiber H (1993). CD4-positive and B lymphocytes in transplantation immunity. I. Promotion of tumor allograft rejection through elimination of CD4-positive lymphocytes.. Transplantation, 55(6), 1349 - 1355.
    • Yin L, Lowe P, Stauss HJ (1993). T cell recognition of a point mutation in the P21 Ras protein.. Leukemia, 7 Suppl 2, S27 - S30.
    • Yin L, Poirier G, Neth O, Hsuan JJ, Totty NF, Stauss HJ (1993). Few peptides dominate cytotoxic T lymphocyte responses to single and multiple minor histocompatibility antigens.. Int Immunol, 5(9), 1003 - 1009.
    • Kwan-Lim GE, Ong T, Aosai F, Stauss H, Zamoyska R (1993). Is CD8 dependence a true reflection of TCR affinity for antigen?. Int Immunol, 5(10), 1219 - 1228.

    1992

    • DUBOIS D, LEDERMANN JA, LINK EM, STAUSS H, COLLINS M (1992). MALIGNANT-MELANOMA. LANCET, 340(8825), 948 - 951.
    • Stauss HJ, Davies H, Sadovnikova E, Chain B, Horowitz N, Sinclair C (1992). Induction of cytotoxic T lymphocytes with peptides in vitro: identification of candidate T-cell epitopes in human papilloma virus.. Proc Natl Acad Sci U S A, 89(17), 7871 - 7875.
    • Moots RJ, Samberg NL, Pazmany L, Frelinger JA, McMichael AJ, Stauss HJ (1992). A cross-species functional interaction between the murine major histocompatibility complex class I alpha 3 domain and human CD8 revealed by peptide-specific cytotoxic T lymphocytes.. Eur J Immunol, 22(6), 1643 - 1646. doi:10.1002/eji.1830220645

    1991

    • Stauss HJ (1991). Peptides feeling groovy.. Curr Biol, 1(5), 328 - 330.
    • Lalani EN, Berdichevsky F, Boshell M, Shearer M, Wilson D, Stauss H, Gendler SJ, Taylor-Papadimitriou J (1991). Expression of the gene coding for a human mucin in mouse mammary tumor cells can affect their tumorigenicity.. J Biol Chem, 266(23), 15420 - 15426.
    • Marvel J, Lightstone E, Samberg NL, Ettinghausen D, Stauss HJ (1991). The CD45RA molecule is expressed in naive murine CTL precursors but absent in memory and effector CTL.. Int Immunol, 3(1), 21 - 28.
    • Aosai F, Ohlen C, Ljunggren HG, Höglund P, Franksson L, Ploegh H, Townsend A, Kärre K, Stauss HJ (1991). Different types of allospecific CTL clones identified by their ability to recognize peptide loading-defective target cells.. Eur J Immunol, 21(11), 2767 - 2774. doi:10.1002/eji.1830211118

    1990

    • Perdrizet GA, Ross SR, Stauss HJ, Singh S, Koeppen H, Schreiber H (1990). Animals bearing malignant grafts reject normal grafts that express through gene transfer the same antigen.. J Exp Med, 171(4), 1205 - 1220.
    • Stauss H, Mitchison NA, Yao M (1990). Thy-1-specific helper T cells can provide intramolecular help, but can provide intermolecular help only if the phosphatidylinositol anchor of Thy-1 is replaced by a membrane insert.. Eur J Immunol, 20(7), 1491 - 1495. doi:10.1002/eji.1830200713

    1989

    • Samberg NL, Scarlett EC, Stauss HJ (1989). The alpha 3 domain of major histocompatibility complex class I molecules plays a critical role in cytotoxic T lymphocyte stimulation.. Eur J Immunol, 19(12), 2349 - 2354. doi:10.1002/eji.1830191225
    • Fisher AG, Goff LK, Lightstone L, Marvel J, Mitchison NA, Poirier G, Stauss H, Zamoyska R (1989). Problems in the physiology of class I and class II MHC molecules, and of CD45.. Cold Spring Harb Symp Quant Biol, 54 Pt 2, 667 - 674.

    1988

    • PERDRIZET GA, SCHREIBER H, FINK MA, STARR B, STAUSS HJ, ROSS SR (1988). GENETIC MANIPULATION CAN OVERCOME IMMUNOLOGICAL-UNRESPONSIVENESS IN INDIVIDUALS WITH ESTABLISHED CANCER. FASEB J, 2(6), A1635 - A1635.
    • Schreiber H, Ward PL, Rowley DA, Stauss HJ (1988). Unique tumor-specific antigens.. Annu Rev Immunol, 6, 465 - 483. doi:10.1146/annurev.iy.06.040188.002341

    1987

    • Watts S, Vogel JM, Harriman WD, Itoh T, Stauss HJ, Goodenow RS (1987). DNA sequence analysis of the C3H H-2Kk and H-2Dk loci. Evolutionary relationships to H-2 genes from four other mouse strains.. J Immunol, 139(11), 3878 - 3885.
    • Stauss HJ, Fink MA, Starr B, Schreiber H (1987). Identification of a gene encoding a tumor-specific antigen that causes tumor rejection.. Haematol Blood Transfus, 31, 308 - 313.

    1986

    • Stauss HJ, Linsk R, Fischer A, Watts S, Banasiak D, Haberman A, Clark I, Forman J, McMillan M, Schreiber H (1986). Isolation of the MHC genes encoding the tumour-specific class I antigens expressed on a murine fibrosarcoma.. J Immunogenet, 13(2-3), 101 - 111.
    • Philipps C, Stauss HJ, Wortzel RD, Schreiber H (1986). A novel MHC class I molecule as a tumour-specific antigen. Correlation between the antibody-defined and the CTL-defined target structure.. J Immunogenet, 13(2-3), 93 - 99.
    • Wortzel RD, Stauss HJ, Van Waes C, Schreiber H (1986). The complexity of unique tumor-specific antigens.. Symp Fundam Cancer Res, 38, 161 - 182.
    • Stauss HJ, Van Waes C, Fink MA, Starr B, Schreiber H (1986). Identification of a unique tumor antigen as rejection antigen by molecular cloning and gene transfer.. J Exp Med, 164(5), 1516 - 1530.

    1985

    • SCHREIBER H, GOODENOW RS, PHILIPPS C, FLOOD PM, STAUSS HJ (1985). MHC GENE ACTIVATION, ONCOGENESIS AND DIFFERENTIATION. J LEUKOCYTE BIOL, 38(1), 48 - 48.
    • Wortzel RD, Stauss HJ, Van Waes C, Schreiber H (1985). Dissection of tumour-specific antigenicity.. Cancer Surv, 4(1), 115 - 134.
    • STAUSS HJ, GOODENOW RS, MCMILLAN M, PHILIPPS C, VANWAES C, WOMACK JE, FORMAN J, FITCH FW, SCHREIBER H (1985). DIFFERENCES BETWEEN ALIEN AND TUMOR-SPECIFIC CLASS-I MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) MOLECULES DEFINED BY THE ANALYSIS OF GENE TRANSFECTANTS. P AM ASSOC CANC RES, 26(MAR), 312 - 312.
    • STAUSS HJ, GOODENOW RS, VANWAES C, PHILIPPS C, ROTHSTEIN J, SCHREIBER H (1985). IDENTIFICATION OF A T-CELL-DEFINED UNIQUE TUMOR-SPECIFIC TRANSPLANTATION ANTIGEN FOLLOWING MOLECULAR-CLONING AND GENE-TRANSFER. FED PROC, 44(3), 550 - 550.

    • Xue SA, Gao L, Thomas S, Hart DP, Xue JZ, Gillmore R, Voss RH, Morris E, Stauss HJ (). Development of a WT1-TCR for clinical trials: engineered patient T cells can eliminate autologous leukemia blasts in NOD/SCID mice. Haematologica, , - . doi:10.3324/haematol.2009.006486
    • Ramirez R, Xue SA, Holler A, Keda J, Hadjiminas D, Healy V, Dina R, parry SC, Bellantuono I, Ghani Y, Coombes RC, Eaxman J, Stauss HJ (). Dendritic-cell immunization induces non-protective WY1-specific CYTL responses in mouse. Journal of Immunotherapy, , - .
    • Carpenter B, Ghorashian S, Nicholson E, Griffin J, Ahmadi M, Holler A, Flutter B, Edwards N, Stauss H, Morris E, Chakraverty R (). Targeting Therapeutic T Cells to Tumour Niches.
    • Ghorashian S, Carpenter B, Holler A, Nicholson E, Ahmadi M, Zech M, Bennett C, Xue S, Morris E, Stauss H, Chakraverty R (). CD4 Cells Engineered to Express an MHC Class I Restricted TCR Can Rescue CD8 Cells Tolerized to Tumour-Associated Antigens.
    • Griffin J, Carpenter B, Nicholson E, Xue S, Pule M, Stauss H, Chakraverty R (). In Vivo Selection of Mycophenolate Mofetil-Resistant T Cells for Adoptive Immunotherapy.